Építés alatt – nem éles oldal
Belépés

What researchers published on Mielodiszplasztikus szindróma (MDS)

8389 papers, newest first.

Showing 20 of 8389

  • Clinical and molecular characteristics associated with megakaryocytic dysplasia in patients with myelodysplastic syndromes.Hematology (Amsterdam, Netherlands)
  • ÁttekintésNovel and emerging agents for myelodysplastic syndromes/neoplasms.Expert opinion on investigational drugs
  • Oral Versus Intravenous Hypomethylating Agents in Myelodysplastic Syndromes and Acute Myeloid Leukemia: A Multicenter Real-World Toxicity Comparison.Acta haematologica
  • New diagnostic criteria can inflate myelodysplastic syndrome survival estimates.Journal of the National Cancer Institute
  • SRSF2 mutations contribute to bone marrow immune microenvironment alterations.Cell death & disease
  • An Unusual Presentation of Erythropoietin-Induced Acute Monoarthritis in a Patient With Myelodysplastic Syndrome and Behçet Disease: A Case Report.The Journal of rheumatology
  • Fever of Unknown Origin in Myelodysplastic Syndrome: Clinical and Laboratory Features of a Chinese Cohort.Journal of clinical medicine
  • AI-assisted single-cell transcriptomics defines immunosuppressive ecosystem states and CD274-centered communication networks in myelodysplastic syndrome.Frontiers in cell and developmental biology
  • Optimizing Reduced-Intensity Conditioning for Older Patients with AML and MDS: A Large-Scale Analysis from the CIBMTR.Blood
  • Aligning Clinical Trial Reporting: A systematic analysis and position statement by the International Consortium for MDS.Blood
  • Teclistamab in multiple myeloma with coexisting myelodysplastic syndrome or acute myeloid leukemia.Haematologica
  • Exploring neuropsychological alterations in VEXAS syndrome.Clinical and experimental medicine
  • EsetismertetésMyelodysplastic Syndrome With Isolated del(5q) Coexisting With Cold Agglutinin Disease Presenting as Unexplained Hyperbilirubinemia.Cureus
  • Development and validation of a baseline interpretable prognostic model for mortality risk stratification in myelodysplastic syndrome patients receiving hypomethylating agent therapy.Current problems in cancer
  • MicroRNA dysregulation in mesenchymal stromal cells in myelodysplastic syndromes and its modulation by azacitidine and bortezomib.Leukemia & lymphoma
  • ÁttekintésSGLT2 Inhibitors and Hemoglobin Improvement in Myelodysplastic Syndromes and Myeloproliferative Neoplasms: Mechanistic Rationale and Emerging Clinical Evidence.Anemia
  • Mesenchymal stromal cells drive immune escape in MDS and sAML through metabolic rewiring of NK cells.Leukemia
  • Integrating functional marrow reserve and molecular risk improves prediction of post-transplant outcomes in HMA-treated myelodysplastic syndromes.Blood neoplasia
  • PreprintPersistent Malignant Stem Cells Drive Relapse After Transplantation in the Myelodysplastic Neoplasms.bioRxiv : the preprint server for biology
  • Luspatercept in Myelodysplastic Syndromes With Ring Sideroblasts: Long Term Outcome and Impact on Non-Erythroid Blood Counts.Hematological oncology